

## AMENDMENTS

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

### Listing of Claims:

1. (Currently amended) A multiparticulate milnacipran composition for oral administration comprising particles ~~consisting of~~ comprising a milnacipran salt complexed with an ion-exchange resin, wherein:
  - (a) the particles lack an impregnating agent; and
  - (b) the particles are coated with an enteric polymer;wherein the composition provides delayed and extended release of milnacipran ~~to~~ and ~~produce~~ produces a therapeutic effect over approximately 24 hours when administered to a patient in need thereof, with diminished incidence or reduced intensity of side effects relative to the side effects resulting from administration of the same dose of milnacipran administered in an immediate release formulation.
2. (Currently amended) The composition of claim 1 wherein the ion-exchange resin particles are less than about 2 ~~millimeter~~ millimeters in diameter.
3. (Original) The composition of claim 1 wherein the ion-exchange resin particles are less than about 500 microns in diameter.
4. (Original) The composition of claim 1 wherein the ion-exchange resin particles are less than about 150 microns in diameter.
5. (Canceled).
6. (Canceled).

7. (Canceled).
8. (Canceled).
9. (Canceled).
10. (Canceled).
11. (Withdrawn) The composition of claim 1 formulated into a dosage form selected from the group consisting of a gel, capsule, soft gelatin capsule, tablet, chewable tablet, crushable tablet, rapidly dissolving tablet, and unit of use sachet or capsule for reconstitution.
12. (Original) The composition of claim 1 formulated into a liquid or liquid suspension.
13. (Canceled).
14. (Canceled).
15. (Previously presented) The milnacipran composition of claim 1, wherein the side effect is nausea.
16. (Withdrawn) The milnacipran composition of claim 14, wherein the side effects are selected from the group consisting of vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysuria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
17. (Previously presented) The milnacipran composition of claim 1, wherein less than approximately 20% of the total milnacipran dose is released in one hour when the formulation is subjected to *in vitro* dissolution in 0.1 N HCl.

18. (Currently amended) The milnacipran composition of claim 17 wherein the milnacipran is released over a period of time is between approximately four and approximately twenty-four hours.
19. (Original) The composition of claim 1 further comprising one or more additional active ingredients.
20. (Currently amended) The composition of claim 19 wherein the active ingredients are ~~selected from the group consisting of~~ analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, ~~anxiolytics~~ anxiolytics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics, or ~~and~~ anti-narcoleptics.
21. (Previously presented) The composition of claim 1 in a dosage form delivering a therapeutically equivalent dose of between 5 and 500 mg milnacipran.
22. (Previously presented) The composition of claim 21 in a dosage form delivering a therapeutically equivalent dose of between 100 and 400 mg milnacipran.
23. (Withdrawn) The milnacipran composition of claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of either dextrogyral or levogyral enantiomers of the milnacipran.
24. (Original) The milnacipran composition of claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of a mixture of milnacipran enantiomers.
25. (Withdrawn) The milnacipran composition of claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of the active metabolite of milnacipran.

26. (Withdrawn) The milnacipran composition of claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of para-hydroxy-milnacipran (F2782).
27. (Original) A method of treating a patient in need thereof comprising administering to the patient the composition of claim 1.
28. (Canceled).
29. (Previously presented) The milnacipran composition of claim 1 wherein less than approximately 20% of the total milnacipran dose is released in two hours when the formulation is subjected to *in vitro* dissolution in 0.1 N HCl.
30. (New) The milnacipran composition of claim 1, wherein the enteric polymer is a cellulose polymer, a polyvinyl acetate phthalate, an acrylic acid polymer, an acrylic acid copolymer, a methacrylic resin, or mixtures thereof.
31. (New) The milnacipran composition of claim 30, wherein the cellulose polymer is cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose acetate succinate.
32. (New) The milnacipran composition of claim 1, wherein the particles further comprise an extended release coating.
33. (New) A method of making a multiparticulate milnacipran composition for oral administration comprising particles comprising milnacipran complexed with an ion-exchange resin comprising:
- (a) complexing a milnacipran salt in the absence of an impregnating agent to make a milnacipran complex; and
  - (b) coating the milnacipran complex with an enteric polymer.

34. (New) A method of treating fibromyalgia comprising administering a therapeutically effective amount of the composition of claim 1 to a subject in need thereof.